ILARIS canakinumab 150 mg powder for injection

国: オーストラリア

言語: 英語

ソース: Department of Health (Therapeutic Goods Administration)

有効成分:

Canakinumab, Quantity: 150 mg

から入手可能:

Novartis Pharmaceuticals Australia Pty Ltd

INN（国際名）:

Canakinumab

医薬品形態:

Injection, powder for

構図:

Excipient Ingredients: sucrose; histidine; histidine hydrochloride monohydrate; polysorbate 80; dilute hydrochloric acid

投与経路:

Subcutaneous

パッケージ内のユニット:

1, 4

処方タイプ:

(S4) Prescription Only Medicine

適応症:

Ilaris is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children aged 2 years or older including: Familial Cold Autoinflammatory Syndrome (FCAS) /Familial Cold Urticaria (FCU); Muckle-Wells Syndrome (MWS); Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA). Ilaris is indicated for the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in patients aged 2 years or older.

製品概要:

Visual Identification: White solid lyophilisate; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store at 2 to 8 degrees Celsius

認証ステータス:

Registered

承認日:

2010-05-10